Constanze Elfgen1,2, Christoph Tausch1, Ann-Katrin Rodewald3, Uwe Güth1,4, Christoph Rageth5, Vesna Bjelic-Radisic2,6, Markus Fleisch2,6, Claudia Kurtz7, Jesus Gonzalez Diaz8, Zsuzsanna Varga3. 1. Breast Center Zurich, Zurich, Switzerland. 2. University of Witten-Herdecke, Witten, Germany. 3. Institute of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland. 4. Faculty of Medicine, University of Basel, Basel, Switzerland. 5. Department of Gynecology and Obstetrics, Breast Center, Hôpitaux Universitaires de Genève, Geneva, Switzerland. 6. Institute of Gynecology and Obstetrics, University Hospital Wuppertal, Wuppertal, Germany. 7. Department of Radiology and Nuclear Medicine, Kantonsspital Luzern, Lucerne, Switzerland. 8. Faculty of Medicine, University of Zurich, Zurich, Switzerland.
Abstract
Purpose: Classical type of lobular neoplasia (LN) encompassing both atypical lobular hyperplasia and classical lobular carcinoma in situ of the breast is a lesion with uncertain malignant potential and has been the topic of several studies with conflicting outcome results. The aim of our study was to clarify outcome-relevant factors and treatment options of classical LN. Methods: We performed a pathological re-evaluation of the preoperative biopsy specimens and a retrospective clinical and radiological data analysis of 160 patients with LN from the Breast Center Zurich. Open surgery was performed in 65 patients, vacuum-assisted biopsy (VAB) in 79 patients, and surveillance after breast core needle biopsy (CNB) in 16 patients. Results: The upgrade rate into ductal carcinoma in situ/invasive cancer was the highest in case of imaging/histology discordance (40%). If the number of foci in the biopsy specimen was ≥3, the upgrade rate in the consecutive surgical specimens was increased (p = 0.01). The association of classical LN with histological microcalcification correlated with shortened disease-free survival (p < 0.01), whereas other factors showed no impact on follow-up. Conclusions: Surveillance or subsequent VAB after CNB of LN is sufficient in most cases. Careful consideration of individual radiological and histological factors is required to identify patients with a high risk of upgrade into malignancy. In those cases, surgical excision is indicated.
Purpose: Classical type of lobular neoplasia (LN) encompassing both atypical lobular hyperplasia and classical lobular carcinoma in situ of the breast is a lesion with uncertain malignant potential and has been the topic of several studies with conflicting outcome results. The aim of our study was to clarify outcome-relevant factors and treatment options of classical LN. Methods: We performed a pathological re-evaluation of the preoperative biopsy specimens and a retrospective clinical and radiological data analysis of 160 patients with LN from the Breast Center Zurich. Open surgery was performed in 65 patients, vacuum-assisted biopsy (VAB) in 79 patients, and surveillance after breast core needle biopsy (CNB) in 16 patients. Results: The upgrade rate into ductal carcinoma in situ/invasive cancer was the highest in case of imaging/histology discordance (40%). If the number of foci in the biopsy specimen was ≥3, the upgrade rate in the consecutive surgical specimens was increased (p = 0.01). The association of classical LN with histological microcalcification correlated with shortened disease-free survival (p < 0.01), whereas other factors showed no impact on follow-up. Conclusions: Surveillance or subsequent VAB after CNB of LN is sufficient in most cases. Careful consideration of individual radiological and histological factors is required to identify patients with a high risk of upgrade into malignancy. In those cases, surgical excision is indicated.
Authors: Mary F Dillon; Enda W McDermott; Arnold D Hill; Ann O'Doherty; Niall O'Higgins; Cecily M Quinn Journal: Ann Surg Oncol Date: 2006-12-07 Impact factor: 5.344
Authors: Melissa P Murray; Chad Luedtke; Laura Liberman; Tatjana Nehhozina; Muzaffar Akram; Edi Brogi Journal: Cancer Date: 2012-11-06 Impact factor: 6.860
Authors: Christoph J Rageth; Elizabeth A M O'Flynn; Katja Pinker; Rahel A Kubik-Huch; Alexander Mundinger; Thomas Decker; Christoph Tausch; Florian Dammann; Pascal A Baltzer; Eva Maria Fallenberg; Maria P Foschini; Sophie Dellas; Michael Knauer; Caroline Malhaire; Martin Sonnenschein; Andreas Boos; Elisabeth Morris; Zsuzsanna Varga Journal: Breast Cancer Res Treat Date: 2018-11-30 Impact factor: 4.872